Drug treatments for obesity/Bibliography: Difference between revisions
imported>Rachael Kirkbride |
imported>Rachael Kirkbride |
||
| Line 2: | Line 2: | ||
==Review Articles== | ==Review Articles== | ||
1 | [1] Magni P. ''et al.'' (2009) Feeding behavior in mammals including humans. ''Ann.N.Y.Acad.Sci.'' 1163:221-232. PMID 19456343 | ||
2 | [2] Coutinho W. (2009)The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. ''Arquivos Brasileiros De Endocrinologia E Metabologia.'' 53:262-270 ''"The most | ||
''widely used anti-obesity agents are sibutramine and orlistat, both available in clinical practice for | ''widely used anti-obesity agents are sibutramine and orlistat, both available in clinical practice for | ||
about a decade."'' | about a decade."'' | ||
3 | [3] Elangbam C.S. (2009). Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns. ''vet pathol''. 26:10-24 ''"This review covers the current state of antiobesity drugs and their safety concerns, and highlights new therapeutic targets and scientific advances toward the development of appropriate animal models by using novel techniques that will aid in understanding pathogenesis and pathophysiology of anorexigen-related safety issues."'' | ||
==Primary Research Papers== | ==Primary Research Papers== | ||
Revision as of 06:08, 7 October 2009
- Please sort and annotate in a user-friendly manner. For formatting, consider using automated reference wikification.
Review Articles
[1] Magni P. et al. (2009) Feeding behavior in mammals including humans. Ann.N.Y.Acad.Sci. 1163:221-232. PMID 19456343
[2] Coutinho W. (2009)The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. Arquivos Brasileiros De Endocrinologia E Metabologia. 53:262-270 "The most widely used anti-obesity agents are sibutramine and orlistat, both available in clinical practice for about a decade."
[3] Elangbam C.S. (2009). Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns. vet pathol. 26:10-24 "This review covers the current state of antiobesity drugs and their safety concerns, and highlights new therapeutic targets and scientific advances toward the development of appropriate animal models by using novel techniques that will aid in understanding pathogenesis and pathophysiology of anorexigen-related safety issues."
Primary Research Papers
[4] Rossner S, Sjostrom L, Noack R, Meinders A, Noseda G. (2000). Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obesity Research.8:41-61 "Orlistat administered for 2 years promotes weight loss and minimizes weight regain. Additionally, orlistat therapy improves lipid profile, blood pressure, and quality of life."
[5] Hauptman J, Lucas C, Boldrin M, Collins H. (2000). Orlistat in the Long-term Treatment of Obesity in Primary Care Settings. Arch Fam Med 9:160–167 "More patients treated with orlistat lost 5% or more of their initial weight in year 1 (48.8% and 50.5% of patients in the 60-mg and 120-mg groups, respectively) compared with placebo (30.7%; P,.001), and approximately 34% of patients in the orlistat groups sustained weight loss of 5% or greater over 2 years compared with 24% in the placebo group (P,.001)."
Books
1. Rang H, Dale M, Ritter J, Flower R. (2007). Pharmacology. Churchill Livingstone, Elsevier. 417-418.